AC699 for Breast Cancer

Recruiting at4 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Accutar Biotechnology Inc

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing AC699, a new oral drug, in patients with a specific type of advanced breast cancer. AC699 works by breaking down estrogen receptors, which helps to stop the cancer from growing. Another drug being tested is AZD9496, which also targets estrogen receptors to prevent cancer growth.

Research Team

Eligibility Criteria

This trial is for adults with ER+/HER2- advanced or metastatic breast cancer who have tried at least one line of endocrine therapy. They must be able to swallow pills, have no major GI issues affecting drug absorption, and should not have symptomatic brain metastases requiring high-dose steroids.

Inclusion Criteria

My breast cancer is advanced, can't be surgically removed, and has worsened after standard treatment.

I have gone through menopause.

My organs are functioning well and my blood tests are normal.

Exclusion Criteria

I haven't had major radiation therapy or unresolved side effects in the last 14 days.

I have not had major surgery in the last 21 days or have fully recovered from one within the last 14 days.

I haven't taken any cancer drugs for my advanced breast cancer in the last 14 days.

Treatment Details

Interventions

• AC699 (Selective Estrogen Receptor Modulator)

Trial Overview The study tests AC699's safety, tolerable dosing levels, how the body processes it (pharmacokinetics), and its effectiveness in treating breast cancer. Participants will receive AC699 to determine these outcomes.

Participant Groups

Group I: AC699 Dose Escalation Experimental Treatment 1 Intervention

Participants will receive an assigned dose of AC699 monotherapy during dose escalation. One cycle is defined as 28 days.

Who Is Running the Clinical Trial?

Accutar Biotechnology Inc

Lead Sponsor

Trials

6

Recruited

180+